Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Exercise's secret power on diabetes revealed in new study

NCT ID NCT04754581

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how exercise training changes the way muscles and fat tissue handle insulin in people with type 2 diabetes. About 39 adults aged 30-65 who are sedentary and have type 2 diabetes will take part. Researchers will use PET scans and small tissue samples to measure glucose uptake before and after an exercise program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

Mar 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 30-65 years 2. Men and women 3. Body mass index (BMI) between 25 and 45 kg/m2 4. Sedentary (1 day or less per week of structured exercise) 5. Type 2 diabetes mellitus determined by self-report or by a fasting glucose \>126mg/dl 6. Weight stable (± 2 kg) for prior 3 months 7. Willing to commit to the schedule of assessment visits, including the exercise intervention Exclusion Criteria: 1. Currently taking insulin, injectable incretin mimetics and thiazolidinediones 2. Taking more than two glucose-lowering medications 3. Resting blood pressure ≥ 160/100 mm Hg 4. Triglycerides ≥ 500 mg/dL 5. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise training protocol 6. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 7. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise training 8. Pulse check ("Allen test") indicates participant has poor blood flow in the hands 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year 11. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 12. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 13. Participant is currently taking anti-inflammatory medication or has had inflammatory medication within 1 week prior to screening (including over the counter formulations: e.g. Aleve, Motrin, Ibuprofen, Naproxen, low dose ASA. 14. New onset (\<3 months on a stable regime) hormone replacement therapy 15. Current use of beta-adrenergic blocking agents 16. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 17. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal) 18. Abnormal blood count/anemia, blood transfusion or blood donation within the last 2 months 19. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 20. Current drug or alcohol abuse/dependence 21. Metal implants (pace-maker, aneurysm clips) based on investigator's judgment at screening 22. Not physically capable of performing the exercise required of the study protocols 23. Plans to be away \>2 weeks in the next 3 months 24. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 25. Unable to tolerate MRI or claustrophobia. 26. Nickel allergy 27. Lidocaine allergy 28. Unable or unwilling to communicate with staff or to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AdventHealth Translational Research Institute

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.